HDAC9 and cancer: Romidepsin, an FDA-approved inhibitor of histone deacetylase (HDAC), interacts with zinc ions in the active site of HDAC enzymes to restrain overexpressed HDAC in tumors, restoring normal gene expression and inducing cancer cell apoptosis (73, 74).